State Street’s Kailera Therapeutics KLRA Stock Holding History

State Street’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1M	Buy	+868,160	New	+$19.1M	﹤0.01%	2410

Other funds holding KLRA

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street's KLRA Position: Q2 2026 in Review

State Street opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 868,160 shares worth $19.1M. The stake represents ﹤0.01% of the portfolio and ranks #2410 among its holdings.

100 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

State Street held 868,160 shares of Kailera Therapeutics worth $19.1M as of Q2 2026.
Kailera Therapeutics was a new State Street position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2410 holding.
100 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.